Purified proteins from Leishmania amastigotes-induced delayed type hypersensitivity reactions and remission of collagen-induced arthritis in animal models.
A treatment preparation composed of purified Leishmania (L) antigenic fractions (AS210) induced linear delayed type hypersensitivity (DTH) reactions over a 1-40 microg dose range, in guinea pigs. When a DBA-1 mouse collagen induced arthritis (CIA) model was used to compare AS210 treatment against: a polyvalent vaccine (AS110-1), a monovalent vaccine (AS110-2) and placebo, the AS210 treated mice had the least amount of forepaw inflammation and the lowest mean arthritis scores (MAS). When MAS for day(s) 1-40 were analyzed using one way ANOVA, statistically significant (P < 0.05) differences were seen for the following study groups: PBS versus Dexamethasone and PBS versus AS210. Subsequently, the ANOVA analysis results were corroborated by the Mann-Whitney test: analysis of the first group (P < 0.001) and analysis of the second group (P < 0.001). Comparison between dexamethasone and AS210 at different time intervals by Mann-Whitney test were as follows: day 0-day 5 both treatments had equal values (P = 1.00), from day-7 to 20 AS210 treatment had lower MAS values than dexamethasone (P = 0.037), and from day-21 to 30, AS210 MAS were similar to dexamethasone values (P = 0.319). No statistical difference was observed between AS110-1, AS110-2, and placebo groups.
O'Daly
Jose Antonio
JA
Astralis LTD., Fairfield, NJ 07004, USA. joseodaly@aol.com
Gleason
J P
JP
Peña
G
G
Colorado
I
I
D000818:Animals; D000953:Antigens, Protozoan / Q000008:administration & dosage / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000302:isolation & purification* / Q000494:pharmacology; D001169:Arthritis, Experimental / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D001327:Autoimmune Diseases / Q000628:therapy; D016207:Cytokines / Q000378:metabolism; D006168:Guinea Pigs; D006801:Humans; D006968:Hypersensitivity, Delayed; D016233:Immunotherapy, Active; D007891:Leishmania / Q000276:immunology*; D008565:Membrane Proteins / Q000276:immunology; D051379:Mice; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000627:therapeutic use; D011897:Random Allocation; D013601:T-Lymphocytes / Q000276:immunology
D000953:Antigens, Protozoan; D018501:Antirheumatic Agents; D016207:Cytokines; D008565:Membrane Proteins; D016052:Protozoan Vaccines